首页> 外国专利> Methods and compositions for pre-symptomatic or post-symptomatic diagnosis of alzheimer's disease and other neurodegenerative disorders

Methods and compositions for pre-symptomatic or post-symptomatic diagnosis of alzheimer's disease and other neurodegenerative disorders

机译:在症状前或症状后诊断阿尔茨海默氏病和其他神经退行性疾病的方法和组合物

摘要

Methods, compositions and apparatus (e.g., test kits, test systems, reagents, related computer software, calculators, etc.) for pre-symptomatic or post-symptomatic diagnosis of Alzheimer's Disease or other disorders associated with the formation of β-amyloid deposits (e.g., plaques) and/or β-amyloid fibrils. Also, methods, compositions and apparatus assessing the efficacy of treatments for such disorders. Sample cells, tissue or body fluid are obtained from a human or animal subject and analyzed to determine whether or to what extent certain mitochondrial DNA control region (mtDNA CR). Significantly elevated numbers of these mtDNA CR mutations may indicate that the subject suffers from, or is at increased risk for development of, Alzheimer's Disease or other disorders associated with the formation of β-amyloid deposits (e.g., plaques) and/or β-amyloid fibrils. A significant decrease in the numbers of these mtDNA CR mutations during treatment for the disorder may indicate that the treatment is effective.
机译:在症状前或症状后诊断阿尔茨海默氏病或​​其他与β-淀粉样蛋白沉积物相关的疾病的方法,组合物和设备(例如,测试套件,测试系统,试剂,相关的计算机软件,计算器等) (例如噬菌斑)和/或β-淀粉样蛋白原纤维。同样,评估用于治疗此类疾病的功效的方法,组合物和设备。从人或动物受试者获得样品细胞,组织或体液并进行分析,以确定是否或在何种程度上确定了线粒体DNA控制区(mtDNA CR)。这些mtDNA CR突变的数量显着升高可能表明该受试者患有阿尔茨海默氏病或​​与β-淀粉样蛋白沉积物(例如斑块)和/或β-淀粉样蛋白形成有关的其他疾病,或处于发展风险中原纤维。在治疗该疾病的过程中,这些mtDNA CR突变数量的显着减少可能表明该治疗有效。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号